Dyadic International

Yahoo Finance • 2 months ago

Dyadic anticipates $500,000 milestone and targets commercialization ramp through 2026

Earnings Call Insights: Dyadic International, Inc. (DYAI) Q2 2025 MANAGEMENT VIEW * Joseph P. Hazelton, President & COO, stated Dyadic has shifted from a platform-focused R&D company to a commercially-driven biotechnology business, emp... Full story

Yahoo Finance • 2 months ago

Earnings call transcript: Dyadic Q2 2025 sees revenue growth, stock dips

Dyadic International Inc. (DYAI) reported its financial results for the second quarter of 2025, showing significant revenue growth but a continued net loss. The company posted an EPS of -0.06, matching forecasts, while revenue slightly exc... Full story

Yahoo Finance • 2 months ago

Dyadic International Inc (NASDAQ:DYAI) Reports Mixed Q2 2025 Earnings Amid Strategic Rebranding

Dyadic International Inc (NASDAQ:DYAI [https://www.chartmill.com/stock/quote/DYAI]) reported its second-quarter 2025 financial results, delivering mixed performance against analyst expectations. The company, which recently rebranded as Dya... Full story

Yahoo Finance • 2 months ago

Dyadic Reports Second Quarter 2025 Financial Results and Highlights of Recent Company Progress

Completed Strategic Leadership and Operational Transformation from R&D to Commercial OperationsRebranded as Dyadic Applied BioSolutions to Reflect Our New Operational PrioritiesFull Redesign of Corporate Website to Prioritize Commercial Ex... Full story

Yahoo Finance • 2 months ago

Dyadic to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025

JUPITER, Fla., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engine... Full story

Yahoo Finance • 2 months ago

UPDATE: Dyadic International, Inc. Announces Pricing of Public Offering of 6,052,000 Shares of Common Stock

JUPITER, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic” or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional inpu... Full story

Yahoo Finance • 2 months ago

Dyadic International, Inc. Announces Pricing of Public Offering of 6,052,000 Shares of Common Stock

JUPITER, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic” or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional inpu... Full story

Yahoo Finance • 2 months ago

Wednesday's after hours session: top gainers and losers

After the closing bell on Wednesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. [postmarket] GAINERS TICKER CHANGE COMMENT HTOOW [https://www.chartmill.com/st... Full story

Yahoo Finance • 2 months ago

Dyadic International, Inc. Announces Proposed Public Offering of Common Stock

JUPITER, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic” or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional inpu... Full story

Yahoo Finance • 2 months ago

Dyadic International receives Nasdaq notice for minimum bid price deficiency

Dyadic International , Inc. (NASDAQ:DYAI) announced Wednesday it received a notice from the Nasdaq Stock Market LLC indicating that the company’s common stock failed to maintain the minimum bid price of $1 per share over the past 30 consec... Full story

Yahoo Finance • 3 months ago

Dyadic rebrands as Applied BioSolutions to focus on commercial growth

JUPITER, Fla. - Dyadic International, Inc. (NASDAQ:DYAI) announced Wednesday it will begin operating under the name Dyadic Applied BioSolutions in 30 days, signaling a strategic shift from research to commercial operations. The company, cu... Full story

Yahoo Finance • 4 months ago

Dyadic Announces Leadership Change as Part of Ongoing Strategic Shift to Focus on High Demand Ancillary Proteins for Life Sciences, Nutrition, and Industrial Applications

Rapid commercial validation has been achieved through key partnerships disrupting high value/high growth marketsLeadership team realigned in order to enable execution of ancillary protein strategyDyadic is well positioned to seize on geopo... Full story

Yahoo Finance • 5 months ago

Dyadic to Present at World Vaccine Congress | Washington

JUPITER, Fla., April 16, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company that utilizes its microbial production platforms to develop commercial c... Full story

Yahoo Finance • 6 months ago

Dyadic Reports 2024 Year-End Financial Results and Business Updates

Strongrevenueperformance,includingapproximately$1.9millionmilestoneandlicenserevenuerecognizedin2024Up to $7.5 million in grants awarded from CEPI and Gates Foundation intended to accelerate the C1 platform developmenttimeline to manufactu... Full story

Yahoo Finance • 7 months ago

Dyadic to Attend Multiple Industry Events in March

JUPITER, Fla., March 06, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in... Full story

Yahoo Finance • 2 years ago

Dyadic Attends Investor Events in December

JUPITER, Fla., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for... Full story

Yahoo Finance • 2 years ago

Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate

Primary endpoint met Demonstrated safety and reactogenicity of DYAI-100 recombinant proteinC1-cell produced antigen was both safe and well-toleratedNo Serious Adverse Events reportedFinal Clinical Study Report available in the coming weeks... Full story

Yahoo Finance • 2 years ago

Dyadic’s C1 Platform to be Used to Produce Vaccines for Humans and Animals in Africa

JUPITER, Fla., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platfo... Full story

Yahoo Finance • 2 years ago

Dyadic Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Received an upfront payment of $0.6 million in October for product development and licensing of our Dapibus™ platform for animal-free dairy enzyme products DYAI-100 Phase 1 clinical trial top-line results expected in December 2023 New re... Full story

Yahoo Finance • 2 years ago

Dyadic to Present at Industry Events in November

JUPITER, Fla., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for... Full story